Drug Trial Radar · NCT05765812
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
116
Planned (sponsor's estimate)
Start
May 15, 2023
Primary completion
Sep 2028
Study completion Sep 2028
Sponsor
- Lead sponsor
- Debiopharm International SAIndustry
- Sponsor type
- Industry
- First posted
- Mar 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of zedoresertib combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and to characterize the safety and tolerability of these combinations in adult participants with glioblastoma (GBM). Arm B which was previously added to the protocol, has been permanently halted per the safety monitoring committees' decision on the safety findings of this arm. The primary purpose of Phase 1 (Dose expansion) of the study is to assess the doses studied under Phase 1 (Dose Escalation) Arm A and identify the recommended dose (RD) for further development. The Phase 2 will start once the RD Phase 1 has been defined. The primary objective of Phase 2 is to assess the efficacy of zedoresertib at the RD for further development in combination with TMZ, compared to the standard of care (SOC) in adult participants with GBM.
Conditions
- Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
- Astrocytoma, Grade III
Interventions
ZedoresertibDrug
Administered as capsules.
TemozolomideDrug
Administered as capsules.
RadiotherapyRadiation
Administered in accordance with the local clinical practice and applicable Radiation Therapy Oncology Group (RTOG) or the European Organization for Research and Treatment of Cancer (EORTC) guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 (Dose Escalation): Number of Participants Experiencing Dose-limiting Toxicities (DLTs)Time frame: Phase 1: Arm A: Cycle 1 (Cycle=28 days); Arms B and C: Up to approximately 1.8 months
- Phase 1 (Dose Escalation): Number of Participants With At Least One Treatment-emergent Adverse Event (TEAE)Time frame: Up to 30 days after the end of treatment (Arm A: Up to approximately 26 months and Arms B and C: Up to approximately 3.5 months)
- Phase 1 (Dose Escalation): Number of Participants With Clinically Significant Abnormalities in Laboratory, Vital Signs, Electrocardiogram (ECG), and Echocardiogram (ECHO) ParametersTime frame: Up to 30 days after the end of treatment (Arm A: Up to approximately 26 months and Arms B and C: Up to approximately 3.5 months)
- Phase 1 (Dose Escalation): Change From Baseline in Karnofsky Performance Status (KPS) ScoreTime frame: Until disease progression or end of study (approximately 66 months)
- Phase 1 (Dose Expansion): Number of Participants With At Least One Treatment-emergent Adverse Event (TEAE)Time frame: Up to approximately 26 months
- Phase 1 (Dose Expansion): Change from Baseline in Tumor Size Assessed by Objective Response (OR) as per Response Assessment in Neuro-oncology (RANO) CriteriaTime frame: From the start of study treatment until disease progression or end of study (up to approximately 66 months)
- Phase 1 (Dose Expansion): Plasma Concentration of Zedoresertib and its MetaboliteTime frame: Predose and at multiple timepoints up to 6 hours post dose up to Day 15 of Cycle 1 (Cycle=28 days)
- Phase 1 (Dose Expansion): Pharmacodynamic(s) PDy, Change from baseline in Phosphorylated Cell Division Cycle (pCDC2)Time frame: Predose and 4 to 6 hours post dose on Day 10 of Cycle 1 (Cycle=28 days)
- Phase 2: Overall Survival (OS)Time frame: From the start of study treatment until death from any cause or end of study (up to approximately 66 months)
Locations
16 sites in 3 countries. Site status is shown where the registry gives one.
Northwestern Memorial Hospital
Chicago, Illinois · Recruiting
New York University Langone Medical Center
New York, New York · Recruiting
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Baylor Scott & White Research Institute
Dallas, Texas · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas · Recruiting
Huntsman Cancer Institute
Salt Lake City, Utah · Recruiting
Fred Hutchinson Cancer Research Center
Seattle, Washington · Recruiting
Hospital Universitario Vall d'Hebron
Barcelona, Spain · Recruiting
Hospital Universitario Donostia
Donostia / San Sebastian, Spain · Recruiting
Clinica Universidad de Navarra (CUN)
Madrid, Spain · Recruiting
South Texas Accelerated Research Therapeutics (START)
Madrid, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Clinica Universidad de Navarra (CUN)
Pamplona, Spain · Recruiting
Hospital Clinico Universitario de Valencia
Valencia, Spain · Recruiting
Universitaetsspital Zuerich
Zurich, Switzerland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.